All Thayer Events
Building Dynamic, Functional Proteins to Understand and Treat Disease
12:00pm - 1:00pm EST
Meeting ID: 967 6722 3558
Natural proteins have evolved to perform functions that enable life. To perform their functions, proteins often form complexes with other biomolecules and undergo structural changes in response to distal perturbations, termed allostery.
How can we engineer new proteins for artificial functions in cells and tissues?
In this talk, I will describe three ways that we can build new functions in proteins:
- the de novo design of a versatile protein-based sense/response system. In this project, we computationally designed a new small molecule binding site in a protein-protein interface to couple small molecule detection to several outputs: fluorescence, luminescence, and cell survival;
- ongoing work using biophysical characterization techniques and computational protein design to understand the intramolecular signal transduction mechanism of a model transcription factor, which opens the door to a deeper understanding of the molecular underpinnings of allostery and the design of new allosteric proteins;
- our recent project to combine computational and experimental protein engineering methods to rapidly build potent SARS-CoV-2-neutralizing biotherapeutics.
These projects introduce a platform for characterizing complex disease mechanisms, building new antiviral therapeutics, and engineering protein systems with dynamic components.
About the Speaker(s)
Postdoctoral Fellow, UC San Francisco
Glasgow is a protein engineer with research interests in molecular biophysics and evolution. She graduated from Johns Hopkins University with a BS in biomedical engineering and research experience in materials science. As a PhD student at UC Berkeley, she engineered an ancient bacterial secretion system to export biopolymers for applications in biomaterials. Now as a postdoctoral fellow at UC San Francisco, she is using computational and experimental methods to build new protein-based systems for artificial functions and developing SARS-CoV-2 therapeutics.
For more information, contact Ashley Parker at email@example.com.